ClinicalTrials.gg
RecruitingNCT07074015Updated Jun 22, 2026

IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Specimens

An interventional study of Use of IntelliWell to identify and localize sperm for ICSI in Infertility and Azoospermia, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Primary conditionAzoospermiaRegistry: InfertilityReclassifiedWhy we changed it
Registry
Infertility — the first condition term the registry derived for this study.
ClinicalTrials.gg
Azoospermia
Why
  1. The study's listed conditions name Azoospermia, a narrower term within Infertility.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

This study will help determine whether an AI-assisted microwell platform (IntelliWell) can identify rare sperm cells in testicular samples found to not have sperm by conventional analysis. Instead of discarding testicular tissue which was found to be non-sperm bearing by conventional analysis the testicular tissue will be processed using IntelliWell and, if sperm is found and verified by embryologists, it may be used for intracytoplasmic sperm injection (ICSI).

02

Conditions studied

  • Infertility
  • Azoospermia

Browse trials for

Keywords

  • infertility
  • azoospermia
  • micro-TESE
03

In context

Azoospermia Reclassified

59 studies on the registry are indexed under Azoospermia; 17 are open to participants now.

This study's planned enrollment of 20 is below the median of 57 across 32 interventional studies indexed under Azoospermia.

Browse Azoospermia studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,267 studies on the registry; 228 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Compared within Azoospermia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects presenting to Brigham and Women's or Faulkner urology clinic with infertility with clinical non-obstructive azoospermia (clinical diagnosis based on two semen analyses, physical examination, and hormonal testing).
  2. Male subjects undergoing micro-surgical testicular sperm extraction surgery at Brigham and Women's Hospital.
  3. Surgically extracted sperm which are not found to have clinically usable quantities of sperm after standard of care manual processing for which samples would otherwise be discarded and the procedure deemed unsuccessful.

Exclusion criteria

Exclusion Criteria:

1. Female subject (with whom male subjects intends to conceive with surgically extracted sperm) cannot or will not provide her for study participation. She will undergo ICSI at BWH with BWH embryology.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    IntelliWell Arm

    Device: Use of IntelliWell to identify and localize sperm for ICSI

Interventions

  • DeviceUse of IntelliWell to identify and localize sperm for ICSI

    The experimental arm will have surgically extracted testicular sperm processed with IntelliWell. If identified and confirmed by embryology, cryopreservation of sperm will occur. On day of ICSI, thaw of testicular sperm will occur and be processed by IntelliWell for identification and localization for use in ICSI.

06

What researchers measure

Primary outcomes

  1. Sperm detection rate by IntelliWell (sperm/min)

    Time frame: Date of surgery and date of ICSI

  2. Sperm retrieval success rate

    Defined as at least one ICSI-grade sperm retrieved from IntelliWell

    Time frame: Date of surgery and date of ICSI

Secondary outcomes

  1. Total number of sperm detected in IntelliWell in fresh sample

    Time frame: Date of surgery

  2. Total number of sperm detected by IntelliWell in test-thaw samples

    Time frame: Day of surgery

  3. Total number of sperm detected by IntelliWell on day of ICSI

    Time frame: Date of ICSI

  4. Time to first sperm detection and time to 10 sperm

    Time frame: Date of surgery and date of ICSI

  5. Number of IntelliWell-identified sperm verified by embryology

    Time frame: Date of surgery and date of ICSI

  6. Number of sperm retrieved and approved for ICSI

    Time frame: Date of ICSI

  7. Total IntelliWell search time

    Time frame: Date of surgery and date of ICSI

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kathrins M, Abhyankar N, Shoshany O, Liebermann J, Uhler M, Prins G, Niederberger C. Post-thaw recovery of rare or very low concentrations of cryopreserved human sperm. Fertil Steril. 2017 Jun;107(6):1300-1304. doi: 10.1016/j.fertnstert.2017.04.016. Epub 2017 May 5. PubMed 28483505 ↗
  • Bernie AM, Mata DA, Ramasamy R, Schlegel PN. Comparison of microdissection testicular sperm extraction, conventional testicular sperm extraction, and testicular sperm aspiration for nonobstructive azoospermia: a systematic review and meta-analysis. Fertil Steril. 2015 Nov;104(5):1099-103.e1-3. doi: 10.1016/j.fertnstert.2015.07.1136. Epub 2015 Aug 8. PubMed 26263080 ↗
  • Berger AJ, Raup V, Abou Ghayda R, Lanes A, Kathrins M. Inability to obtain sperm for fresh IVF cycles: analysis and incidence of outcomes using a database from the United States. Fertil Res Pract. 2020 Aug 11;6:14. doi: 10.1186/s40738-020-00082-3. eCollection 2020. PubMed 32793376 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
Jul 20, 2025
StartActual
Apr 16, 2026
Primary completionEst.
Nov 15, 2027
CompletionEst.
Dec 1, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07074015
Responsible party
Martin Kathrins, M.D. (Principal Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
Jul 20, 2025
Start date
Apr 16, 2026
Primary completion
Nov 15, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Martin Kathrins, MD
Contact
mkathrins@bwh.harvard.edu
617-732-6227
Siline Thai
Contact
sthai1@bwh.harvard.edu
617-525-8793

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion